Chinese General Practice ›› 2021, Vol. 24 ›› Issue (9): 1158-1164.DOI: 10.12114/j.issn.1007-9572.2021.00.068
Special Issue: 内分泌代谢性疾病最新文章合集; 消化系统疾病最新文章合集
• Monographic Research • Previous Articles Next Articles
Published:
2021-03-20
Online:
2021-03-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.00.068
[1]NCD Risk Factor Collaboration(NCD-RisC).Worldwide trends in diabetes since 1980:a pooled analysis of 751 population-based studies with 4.4 million participants[J].Lancet,2016,387(10027):1513-1530.DOI:10.1016/S0140-6736(16)00618-8. [2]GBD 2015 Mortality and Causes of Death Collaborators.Global,regional,and national life expectancy,all-cause mortality,and cause-specific mortality for 249 causes of death,1980—2015:a systematic analysis for the Global Burden of Disease Study 2015[J].Lancet,2016,388(10053):1459-1544.DOI:10.1016/S0140-6736(16)31012-1. [3]MOKDAD A A,LOPEZ A D,SHAHRAZ S,et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010:a systematic analysis[J].BMC Med,2014,12:145.DOI:10.1186/s12916-014-0145-y. [4]BECHMANN L P,HANNIVOORT R A,GERKEN G,et al.The interaction of hepatic lipid and glucose metabolism in liver diseases[J].J Hepatol,2012,56(4):952-964.DOI:10.1016/j.jhep.2011.08.025. [5]GARCIA-COMPEAN D,JAQUEZ-QUINTANA J O,GONZALEZ-GONZALEZ J A,et al.Liver cirrhosis and diabetes:risk factors,pathophysiology,clinical implications and management[J].World J Gastroenterol,2009,15(3):280-288.DOI:10.3748/wjg.15.280. [6]HSIEH P S,HSIEH Y J.Impact of liver diseases on the development of type 2 diabetes mellitus[J].World J Gastroenterol,2011,17(48):5240-5245.DOI:10.3748/wjg.v17.i48.5240. [7]HUANG Y W,YANG S S,FU S C,et al.Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes:a nationwide cohort study[J].Hepatology,2014,60(3):807-814.DOI:10.1002/hep.27212. [8]HUANG Y W,WANG T C,LIN S C,et al.Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes:a nationwide cohort study[J].Clin Infect Dis,2013,57(12):1695-1702.DOI:10.1093/cid/cit603. [9]LI X,GAO Y,XU H,et al.Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients[J].Sci Rep,2017,7(1):9087.DOI:10.1038/s41598-017-09825-7. [10]MAKOL A,KANTHAJE S,DHIMAN R K,et al.Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma[J].Exp Biol Med(Maywood),2018,243(4):323-326.DOI:10.1177/1535370217744511. [11]DESBOIS A C,CACOUB P.Diabetes mellitus,insulin resistance and hepatitis C virus infection:a contemporary review[J].World J Gastroenterol,2017,23(9):1697-1711.DOI:10.3748/wjg.v23.i9.1697. [12]JEPSEN P,WATSON H,ANDERSEN P K,et al.Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients[J].J Hepatol,2015,63(5):1133-1138.DOI:10.1016/j.jhep.2015.07.007. [13]BUTT Z,JADOON N A,SALARIA O N,et al.Diabetes mellitus and decompensated cirrhosis:risk of hepatic encephalopathy in different age groups[J].J Diabetes,2013,5(4):449-455.DOI:10.1111/1753-0407.12067. [14]QI X,PENG Y,LI H,et al.Diabetes is associated with an increased risk of in-hospital mortality in liver cirrhosis with acute upper gastrointestinal bleeding[J].Eur J Gastroenterol Hepatol,2015,27(4):476-477.DOI:10.1097/MEG.0000000000000324. [15]JEON H K,KIM M Y,BAIK S K,et al.Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage[J].Dig Dis Sci,2013,58(11):3335-3341.DOI:10.1007/s10620-013-2802-y. [16]WLAZLO N,VAN GREEVENBROEK M M,CURVERS J,et al.Diabetes mellitus at the time of diagnosis of cirrhosis is associated with higher incidence of spontaneous bacterial peritonitis,but not with increased mortality[J].Clin Sci(Lond),2013,125(7):341-348.DOI:10.1042/CS20120596. [17]MOREAU R,DELèGUE P,PESSIONE F,et al.Clinical characteristics and outcome of patients with cirrhosis and refractory ascites[J].Liver Int,2004,24(5):457-464.DOI:10.1111/j.1478-3231.2004.0991.x. [18]GOH G B B,PAN A,CHOW W C,et al.Association between diabetes mellitus and cirrhosis mortality:the Singapore Chinese Health Study[J].Liver Int,2017,37(2):251-258.DOI:10.1111/liv.13241. [19]EL-SERAG H B,TRAN T,EVERHART J E.Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma[J].Gastroenterology,2004,126(2):460-468.DOI:10.1053/j.gastro.2003.10.065. [20]LIEBER S R,LEE R A,JIANG Y,et al.The impact of post-transplant diabetes mellitus on liver transplant outcomes[J].Clin Transplant,2019,33(6):e13554.DOI:10.1111/ctr.13554. [21]NISHIDA T,TSUJI S,TSUJII M,et al.Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis[J].Am J Gastroenterol,2006,101(1):70-75.DOI:10.1111/j.1572-0241.2005.00307.x. [22]GARCíA-COMPEáN D,JáQUEZ-QUINTANA J O,LAVALLE-GONZáLEZ F J,et al.Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis[J].World J Gastroenterol,2014,20(22):7011-7018.DOI:10.3748/wjg.v20.i22.7011. [23]ELKRIEF L,CHOUINARD P,BENDERSKY N,et al.Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C[J].Hepatology,2014,60(3):823-831.DOI:10.1002/hep.27228. [24]GRANCINI V,TROMBETTA M,LUNATI M E,et al.Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients[J].J Hepatol,2019,70(5):954-962.DOI:10.1016/j.jhep.2019.01.015. [25]RAMOS-PROL A,HERVáS-MARíN D,RODRíGUEZ-MEDINA B,et al.Alterations in carbohydrate metabolism in cirrhotic patients before and after liver transplant[J].Diabetes Res Clin Pract,2015,110(2):123-128.DOI:10.1016/j.diabres.2015.10.002. [26]SALOMONE F,CATANIA M,MONTINERI A,et al.Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1[J].Liver Int,2018,38(7):1206-1211.DOI:10.1111/liv.13669. [27]ORSI E,GRANCINI V,MENINI S,et al.Hepatogenous diabetes:is it time to separate it from type 2 diabetes?[J].Liver Int,2017,37(7):950-962.DOI:10.1111/liv.13337. [28]GRANCINI V,TROMBETTA M,LUNATI M E,et al.Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes:role of severity of liver disease[J].J Hepatol,2015,63(6):1484-1490.DOI:10.1016/j.jhep.2015.08.011. [29]KIM M G,CHOI W C.Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus[J].Korean J Hepatol,2006,12(4):524-529. [30]HOLSTEIN A,HINZE S,THIESSEN E,et al.Clinical implications of hepatogenous diabetes in liver cirrhosis[J].J Gastroenterol Hepatol,2002,17(6):677-681.DOI:10.1046/j.1440-1746.2002.02755.x. [31]HONDA F,HIRAMATSU A,HYOGO H,et al.Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring[J].PloS one,2018,13(4):e0195028.DOI:10.1371/journal.pone.0195028. [32]PETIT J M,HAMZA S,ROLLOT F,et al.Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis[J].Acta Diabetol,2014,51(3):455-460.DOI:10.1007/s00592-013-0538-y. [33]HICKMAN I J,MACDONALD G A.Impact of diabetes on the severity of liver disease[J].Am J Med,2007,120(10):829-834.DOI:10.1016/j.amjmed.2007.03.025. [34]PICARDI A,D'AVOLA D,GENTILUCCI U V,et al.Diabetes in chronic liver disease:from old concepts to new evidence[J].Diabetes Metab Res Rev,2006,22(4):274-283.DOI:10.1002/dmrr.636. [35]DHAHBI J M,MOTE P L,CAO S X,et al.Hepatic gene expression profiling of streptozotocin-induced diabetes[J].Diabetes Technol Ther,2003,5(3):411-420.DOI:10.1089/152091503765691910. [36]KAWAGUCHI T,TANIGUCHI E,ITOU M,et al.Insulin resistance and chronic liver disease[J].World J Hepatol,2011,3(5):99-107.DOI:10.4254/wjh.v3.i5.99. [37]SHANIK M,XU Y,SKRHA J,et al.Insulin resistance and hyperinsulinemia:is hyperinsulinemia the cart or the horse?[J].Diabetes care,2008,33(Suppl 2):S262-268.DOI:10.2337/dc08-s264. [38]ELKRIEF L,RAUTOU P E,SARIN S,et al.Diabetes mellitus in patients with cirrhosis:clinical implications and management[J].Liver Int,2016,36(7):936-948.DOI:10.1111/liv.13115. [39]AYTUG S,REICH D,SAPIRO L E,et al.Impaired IRS-1/PI3-kinase signaling in patients with HCV:a mechanism for increased prevalence of type 2 diabetes[J].Hepatology,2003,38(6):1384-1392.DOI:10.1016/j.hep.2003.09.012. [40]American Diabetes Association.(2)Classification and diagnosis of diabetes[J].Diabetes Care,2015,38 Suppl:S8-16.DOI:10.2337/dc15-S005. [41]GARCíA-COMPEáN D,JáQUEZ-QUINTANA J O,LAVALLE-GONZáLEZ F J,et al.The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis.A prospective study[J].Ann Hepatol,2012,11(2):240-248. [42]ELKRIEF L,RAUTOU P E,SARIN S,et al.Diabetes mellitus in patients with cirrhosis:clinical implications and management[J].Liver Int,2016,36(7):936-948.DOI:10.1111/liv.13115. [43]HAMED A E,ELSAHAR E,ELWAN N M,et al.Managing diabetes and liver disease association[J].Arab J Gastroenterol,2018,19( 4):166-179.DOI:10.1016/j.ajg.2018.08.003. [44]PAPATHEODORIDIS G V,CHRYSANTHOS N,SAVVAS S,et al.Diabetes mellitus in chronic hepatitis B and C:prevalence and potential association with the extent of liver fibrosis[J].J Viral Hepat,2006,13(5):303-310.DOI:10.1111/j.1365-2893.2005.00677.x. [45]LAHOUSEN T,HEGENBARTH K,ILLE R,et al.Determination of glycated hemoglobin in patients with advanced liver disease[J].World J Gastroenterol,2004,10(15):2284-2286.DOI:10.3748/wjg.v10.i15.2284. [46]KUMAR R.Hepatogenous diabetes:an underestimated problem of liver cirrhosis[J].Indian J Endocrinol Metab,2018,22(4):552-559.DOI:10.4103/ijem.IJEM_79_18. [47]American Diabetes Association.Standards of medical care in diabetes——2010[J].Diabetes Care,2010,33(Suppl 1):S11-61.DOI:10.2337/dc10-S011. [48]NATHAN D M,BALKAU B,BONORA E,et al.International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes[J].Diabetes Care,2009,32(7):1327-1334.DOI:10.2337/dc09-9033. [49]IMANO E,KANDA T,NAKATANI Y,et al.Impaired splanchnic and peripheral glucose uptake in liver cirrhosis[J].J Hepatol,1999,31(3):469-473.DOI:10.1016/s0168-8278(99)80039-7. [50]SHMUELI E,WALKER M,ALBERTI G,et al.Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis[J].Hepatology,1993,18(1):86-95.DOI:10.1002/hep.1840180115. [51]GARCíA-COMPEáN D,JáQUEZ-QUINTANA J O,GONZáLEZ-GONZáLEZ J A,et al.Diabetes in liver cirrhosis[J].Gastroenterol Hepatol,2013,36(7):473-482.DOI:10.1016/j.gastrohep.2013.01.012. [52]IMANO E,NISHIDA T,SHIBATA M,et al.Significance of oral glucose tolerance test for the diagnosis of diabetes mellitus in patients with liver cirrhosis[J].Intern Med,1999,38(11):918.DOI:10.2169/internalmedicine.38.918. [53]NISHIDA T.Diagnosis and clinical implications of diabetes in liver cirrhosis:a focus on the oral glucose tolerance test[J].J Endocr Soc,2017,1(7):886-896.DOI:10.1210/js.2017-00183. [54]LENTERS-WESTRA E,SCHINDHELM R K,BILO H J,et al.Haemoglobin A1c:historical overview and current concepts[J].Diabetes Res Clin Pract,2013,99(2):75-84.DOI:10.1016/j.diabres.2012.10.007. [55]BUNN H F,HANEY D N,KAMIN S,et al.The biosynthesis of human hemoglobin A1c.Slow glycosylation of hemoglobin in vivo[J].J Clin Invest,1976,57(6):1652-1659.DOI:10.1172/JCI108436. [56]MARSHALL S M.Standardization of HbA1c:good or bad?[J].Nat Rev Endocrinol,2010,6(7):408-411.DOI:10.1038/nrendo.2010.66. [57]American Diabetes Association.Standards of medical care for patients with diabetes mellitus[J].Diabetes Care,2003,26(Suppl 1):S33-50.DOI:10.2337/diacare.26.2007.s33. [58]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33).UK Prospective Diabetes Study(UKPDS)Group[J].Lancet,1998,352(9131):837-853. [59]HAMED A E,ELWAN N,NAGUIB M,et al.Diabetes association with liver diseases:an overview for clinicians[J].Endocr Metab Immune Disord Drug Targets,2019,19(3):274-280.DOI:10.2174/1871530318666181116111945. [60]ENGLISH E,IDRIS I,SMITH G,et al.The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis:a systematic review[J].Diabetologia,2015,58(7):1409-1421.DOI:10.1007/s00125-015-3599-3. [61]RADIN M S.Pitfalls in hemoglobin A1c measurement:when results may be misleading[J].J Gen Intern Med,2014,29(2):388-394.DOI:10.1007/s11606-013-2595-x. [62]FREEDMAN B I,SHENOY R N,PLANER J A,et al.Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis[J].Perit Dial Int,2010,30(1):72-79.DOI:10.3747/pdi.2008.00243. [63]FALKO J M,O'DORISIO T M,CATALAND S.Spurious elevations in glycosylated hemoglobin(HbA1c)secondary to hypertriglyceridemia[J].Arch Intern Med,1982,142(7):1370-1371.DOI:10.1001/archinte.142.7.1370. [64]HOMA K,MAJKOWSKA L.Difficulties in interpreting HbA(1c)results[J].Pol Arch Med Wewn,2010,120(4):148-154. [65]KOGA M,KASAYAMA S,KANEHARA H,et al.CLD(chronic liver diseases)-HbA1c as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases[J].Diabetes Res Clin Pract,2008,81(2):258-262.DOI:10.1016/j.diabres.2008.04.012. [66]NOMURA Y,NANJO K,MIYANO M,et al.Hemoglobin A1 in cirrhosis of the liver[J].Diabetes Res,1989,11(4):177-180.DOI:10.2337/diabetes.38.8.1072. [67]SEHRAWAT T,JINDAL A,KOHLI P,et al.Utility and limitations of glycated hemoglobin(HbA1c)in patients with liver cirrhosis as compared with oral glucose tolerance test for diagnosis of diabetes[J].Diabetes Ther,2018,9(1):243-251.DOI:10.1007/s13300-017-0362-4. [68]MORSE E E.Mechanisms of hemolysis in liver disease[J].Ann Clin Lab Sci,1990,20(3):169-174. [69]GONZALEZ-CASAS R,JONES E A,MORENO-OTERO R.Spectrum of anemia associated with chronic liver disease[J].World J Gastroenterol,2009,15(37):4653-4658.DOI:10.3748/wjg.15.4653. [70]NADELSON J,SATAPATHY S K,NAIR S.Glycated hemoglobin levels in patients with decompensated cirrhosis[J].Int J Endocrinol,2016,2016:8390210.DOI:10.1155/2016/8390210. [71]TAKAHASHI S,UCHINO H,SHIMIZU T,et al.Comparison of glycated albumin(GA)and glycated hemoglobin(HbA1c)in type 2 diabetic patients:usefulness of GA for evaluation of short-term changes in glycemic control[J].Endocr J,2007,54(1):139-144.DOI:10.1507/endocrj.k06-103. [72]FURUSYO N,KOGA T,AI M,et al.Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study:results from the Kyushu and Okinawa Population Study(KOPS)[J].Diabetologia,2011,54(12):3028-3036.DOI:10.1007/s00125-011-2310-6. [73]IKEZAKI H,FURUSYO N,IHARA T,et al.Glycated albumin as a diagnostic tool for diabetes in a general Japanese population[J].Metabolism,2015,64(6):698-705.DOI:10.1016/j.metabol.2015.03.003. [74]TAHARA Y,SHIMA K.Kinetics of HbA1c,glycated albumin,and fructosamine and analysis of their weight functions against preceding plasma glucose level[J].Diabetes Care,1995,18(4):440-447.DOI:10.2337/diacare.18.4.440. [75]SUWA T,OHTA A,MATSUI T,et al.Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring(CGM)[J].Endocr J,2010,57(2):135-140.DOI:10.1507/endocrj.k09e-234. [76]KOGA M.Glycated albumin;clinical usefulness[J].Clin Chim Acta,2014,433:96-104.DOI:10.1016/j.cca.2014.03.001. [77]LEE J E.Alternative biomarkers for assessing glycemic control in diabetes:fructosamine,glycated albumin,and 1,5-anhydroglucitol[J].Ann Pediatr Endocrinol Metab,2015,20(2):74-78.DOI:10.6065/apem.2015.20.2.74. [78]DOZIO E,DI GAETANO N,FINDEISEN P,et al.Glycated albumin:from biochemistry and laboratory medicine to clinical practice[J].Endocrine,2017,55(3):682-690.DOI:10.1007/s12020-016-1091-6. [79]ISODA H,TAKAHASHI H,EGUCHI Y,et al.Re-evaluation of glycated hemoglobin and glycated albumin with continuous glucose monitoring system as markers of glycemia in patients with liver cirrhosis[J].Biomed Rep,2017,7(3):286.DOI:10.3892/br.2017.928. [80]GOLDSTEIN D E,LITTLE R R,LORENZ R A,et al.Tests of glycemia in diabetes[J].Diabetes Care,2004,27(7):1761-1773.DOI:10.2337/diacare.27.7.1761. [81]DANESE E,MONTAGNANA M,NOUVENNE A,et al.Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes[J].J Diabetes Sci Technol,2015,9(2):169-176.DOI:10.1177/1932296814567227. [82]TRENTI T,CRISTANI A,CIONI G,et al.Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis[J].Ric Clin Lab,1990,20(4):261-267.DOI:10.1007/BF02900711. [83]RODRIGUEZ-SEGADE S,LOJO S,CAMI?A M F,et al.Effects of various serum proteins on quantification of fructosamine[J].Clin Chem,1989,35(1):134-138. [84]SEOK H,HUH J H,KIM H M,et al.1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes[J].Diabetes Metab J,2015,39(2):164-170.DOI:10.4093/dmj.2015.39.2.164. [85]KOGA M.1,5-anhydroglucitol and glycated albumin in glycemia[J].Adv Clin Chem,2014,64:269-301.DOI:10.1016/b978-0-12-800263-6.00007-0. [86]DUNGAN K M,BUSE J B,LARGAY J,et al.1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes[J].Diabetes Care,2006,29(6):1214-1219.DOI:10.2337/dc06-1910. [87]MCGILL J B,COLE T G,NOWATZKE W,et al.Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia:a U.S.trial of the GlycoMark assay[J].Diabetes Care,2004,27(8):1859-1865.DOI:10.2337/diacare.27.8.1859. [88]BECK R,STEFFES M,XING D,et al.The interrelationships of glycemic control measures:HbA1c,glycated albumin,fructosamine,1,5-anhydroglucitrol,and continuous glucose monitoring[J].Pediatr Diabetes,2011,12(8):690-695.DOI:10.1111/j.1399-5448.2011.00764.x. [89]YAMAGISHI S,OHTA M.Serum 1,5-anhydro-D-glucitol levels in liver cirrhosis[J].Acta Diabetol,1998,35(1):65-66.DOI:10.1007/s005920050104. |
[1] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[2] | LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307. |
[3] | YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295. |
[4] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[5] | XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109. |
[6] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[7] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[8] | ZHANG Juan, LI Haifen, LI Xiaoman, YAO Miao, MA Huizhen, MA Qiang. Construction of Recurrence Risk Prediction Model for Diabetic Foot Ulcer on the Basis of Logistic Regression, Support Vector Machine and BP Neural Network Model [J]. Chinese General Practice, 2023, 26(32): 4013-4019. |
[9] | WANG Jiaxin, ZHAO Yali. Domestic and International Assessment Tools for Medical Teamwork: a Systematic Review [J]. Chinese General Practice, 2023, 26(31): 3951-3962. |
[10] | HONG Yuchun, WU Hua, DU Yishan, LI Shuran, SUN Wenmin, YE Mingyu, ZHANG Yongjian, LI Yang. Development of General Practice Diagnostic Terminology and Coding and Empirical Study on Its Application [J]. Chinese General Practice, 2023, 26(31): 3896-3901. |
[11] | WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733. |
[12] | YUAN Xiwei, NAN Yuemin. Research Progress of Structure, Function and Mechanism of Action of Mitofusin 2 in Liver Diseases [J]. Chinese General Practice, 2023, 26(30): 3841-3846. |
[13] | CHENG Jingwei, QIAO Junjun, YIN Zhen, HU Junpeng, WANG Qinghe, LIU Yangqing, WANG Yanfang. Interpretation of ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in Children and Adolescents with Diabetes [J]. Chinese General Practice, 2023, 26(30): 3719-3724. |
[14] | HU Jiayu, REN Lijue, JIN Huanhuan, SUN Tingting, JIN Meina, ZHOU Xueli, WEI Cuiying. The Level of Adipokine Metrnl and Its Relationship with Inflammation and Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome [J]. Chinese General Practice, 2023, 26(30): 3748-3752. |
[15] | XIAO Yuqian, BAI Yanjie, WANG Yan, CHEN Shuying, CHEN Limin, SUN Kexin, WAN Jun. Research Progress of Mitochondrial Transfer in Post-stroke Cognitive Impairment [J]. Chinese General Practice, 2023, 26(30): 3833-3840. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||